Salarius Announces Allowance of New European Patent Covering Seclidemstat
Salarius Pharmaceuticals, Inc. (SLRX)
Company Research
Source: GlobeNewswire
European Patent Office Satisfied Patent Application Meets All Requirements Salarius’ Global Intellectual Property Estate Includes 22 Issued Patents in the U.S., Europe and 12 Other Jurisdictions HOUSTON, March 04, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the U.S. and global intellectual property (IP) portfolio governing its lead investigational drug candidate, Seclidemstat. Seclidemstat is now in a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST). The European Patent Office (EPO) has recently issued a notice of allowance for Patent EP274430 exclusively licensed to Salarius from the University of Utah Research Foundation indicating that the agency is satisfied that the patent application meets all EPO requirements. In all, Salarius holds
Show less
Read more
Impact Snapshot
Event Time:
SLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLRX alerts
High impacting Salarius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SLRX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 10-Q
- 11/1/24 - Form DEFA14A
- SLRX's page on the SEC website